Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 21, 2023

Ocrelizumab Exposure in Relapsing–Remitting MS

Journal of Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Neurology
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
J Neurol 2023 Oct 31;[EPub Ahead of Print], L Kappos, A Traboulsee, DKB Li, A Bar-Or, F Barkhof, X Montalban, D Leppert, A Baldinotti, HM Schneble, H Koendgen, A Sauter, Q Wang, SL Hauser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading